Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23933730 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL1311637 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL15547653 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL9075213 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL3489558 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL28992556 | 0.94 | ALDH1A1 (0.37) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL7153508 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL3513773 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL3344516 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL28900822 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| US-20260124286-A1 | E. COLI FIMH MUTANTS AND USES THEREOF | PFIZER INC. (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025245188-A2 | METHODS OF TREATING LIVER STEATOSIS AND NON-ALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12458689-B2 | Escherichia coli compositions and methods thereof | PFIZER INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250281590-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED ESCHERICHIA COLI SACCHARIDES AND USES THEREOF | PFIZER (US) | 2025-09-11 | — | — | US | disclosed |
| US-12357681-B2 | E. coli FimH mutants and uses thereof | PFIZER INC. (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2025111526-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2025-05-30 | — | — | WO | disclosed |
| US-12291709-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250121044-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | PFIZER (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250114442-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | PFIZER (US) | 2025-04-10 | — | — | US | disclosed |
| CN-106794237-B | Modified host cells and uses thereof | 葛兰素史密丝克莱恩生物有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458689-B2 | Escherichia coli compositions and methods thereof | MRPL21, DDOST, OSTC | ALDH1A1 4186/4885PDE4A 3407/4885KDM4E 903/4885 |
| US-20250281590-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED ESCHERICHIA COLI SACCHARIDES AND USES THEREOF | C5AR1, C3AR1, C5 | ALDH1A1 2911/4885PDE4A 2278/4885KDM4E 1180/4885 |
| US-20260124286-A1 | E. COLI FIMH MUTANTS AND USES THEREOF | Q6ZSR9, MRPL21, F13A1 | ALDH1A1 4732/4885PDE4A 250/4885KDM4E 2657/4885 |
| US-12291709-B2 | Compositions and methods for modulating apolipoprotein (a) expression | APOB, APOL1, LDLR | ALDH1A1 1781/4885PDE4A 3615/4885KDM4E 4777/4885 |
| US-20250114442-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | MRPL21, DDOST, STT3A | ALDH1A1 4075/4885PDE4A 2115/4885KDM4E 3202/4885 |
| US-12357681-B2 | E. coli FimH mutants and uses thereof | MRPL21, MLEC, SELE | ALDH1A1 4120/4885PDE4A 897/4885KDM4E 4265/4885 |
| US-20250121044-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | WIZ, GNE, ENGASE | ALDH1A1 4595/4885PDE4A 3053/4885KDM4E 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.